Search PubMed⌕ Search

Biomedical subjects

C G Schmidt

Publications and source records attributed to C G Schmidt.

At least 181 records · Page 10Linked to original sources
PubMed1979

[Cis-diamminedichloroplatinum(II). A new antineoplastic agent derived from the group of heavy metal complexes (author's transl)].

Platinum coordination complexes represent a new class of antineoplastic agents among which only cis-diamminedichloroplatinum(II) (cis-DDP) has undergone extensive clinical trials. Cis-DDP and some of its congeners share the potential to form DNA-crosslinks with the group of bifunctional alkylating agents, yet cross-resistance is incomplete. The prominent dose-limiting nephrotoxicity can be effectively circumvented by forced diuresis. Cis-DDP not only displays outstanding activity against non-seminomatous testicular cancer but also has a broad spectrum of clinical activity. It ranks very high in activity against bladder cancer and head and neck tumors. Since myelosuppression by cis-DDP is mild, it combines well with other antineoplastic agents. Synergism has been experimentally shown for cyclophosphamide and several other antineoplastic agents. For testicular cancer combination chemotherapy including cis-DDP has become accepted treatment. The simple geometry of platinum coordination complexes allows substitutions of leaving and remaining ligands with anorganic or organic moieties thus altering pharmakokinetic, antineoplastic, and toxic properties in comparison to the parent compound. Mechanism of action, pharmacology, and clinical use of cis-DDP as well as of potentially useful congeners are discussed in this review, since cis-DDP is expected to be available for general use in medical oncology in the near future.

Animals↗
PubMed1979

[Results of treating acute nonlymphoblastic leukaemia in adults (author's transl)].

Between July 1974 and December 1976 a total of 69 patients were treated for acute nonlymphoblastic leukaemia. The mean age was 42 years. Seven had been previously treated. Induction treatment with daunoblastin and cytarabine was given to 67 patients. It produced complete remission in 37 (55.2%) and partial remission in two. Twelve patients received a minimum of two courses of induction treatment without remission (definite treatment failures). Sixteen patients died during the first 30 days after onset of treatment. Treatment to maintain remission consisted of cytarabine and alternating 6-thioguanine, cyclophosphamide, lomustin and daunoblastin. Treatment could be continued as planned in only a quarter of the patients, because of serious side effects in the others. One year after conclusion of the study (31. 12.77) the median remission period was 42, median survival time for all patients 33 weeks (73.5 weeks for those responding and 8 weeks for those not responding to treatment). Age, fever, and chromosomal status of bone-marrow cells had an effect on prognosis.

Acute Disease↗
PubMed1979

[Effect of long-term cytostatic therapy on the hematopoietic stem cells].

CFU-C and diffusion chamber studies were performed in patients with teratocarcinoma, who underwent long term chemotherapy. No significant decline of bone marrow CFU-C or diffusion chamber cell recovery was found during twelve months of cytotoxic treatment. In contrast to the results in these patients the CFU-C-content of the remission marrow in leukemic patients showed a significant decrease in relation to the duration of remission and chemotherapy.

Bleomycin↗
PubMed1979

[Combined chemotherapy of metastasing melanoblastoma using ifosfamide and cis-platinum (II)-diamminodichloride (author's transl)].

15 patients with metastasing melanoblastoma of stage III and IV were treated with a combination of cis-platinum (II)-diamminodichloride and ifosfamide. In 3 cases complete remission occurred, in 5 partial remission with tumour regression of more than 50%. The response rate is around 50% at present. Two cases showed no change after 6 months of chemotherapy.

Adult↗
PubMed1979

[Heavy chain disease: humoral and cellular findings in six patients with mu chain disease (author's transl)].

Clinical and chemical findings in 6 patients with mu-chain disease are reported. In all of these patients a lymphoproliferative disease was observed which by its symptoms resembled CLL. This similarity was underlined by the finding of an impaired response of PBL of the patients to mitogens as PHA, PWM, and Con A. A substantial result of our studies lies in the fact that the presence of mu-chains in the serum does not correlate with a clinically defined entity. Moreover, mu-chains have been observed in a case of benign lymphadenopathy. In one case a good remission of 4 years duration could be induced by the application of cytostatic agents.

Adult↗
PubMed1979

[Combined chemotherapy and radiotherapy of localized and metastasizing Ewing's sarcoma (author's transl)].

Between 1973 and 1978 combined radiotherapy and chemotherapy were given to 22 patients with histologically proven Ewing's sarcoma. The combined chemotherapy consisted of cyclophosphamide, vincristin, adriamycin, as well as dacarbazine in some cases. The neoplasm was a localized one at the beginning of treatment in 14 of the 22. These patients received high-voltage radiotherapy to the primary focus at a focal dose between 42 and 55 Gray (4200-5500 rad), followed by chemotherapy. After 6--8 treatment cycles, adriamycin was replaced by methotrexate. Nine of the 14 patients survived without recurrence for 12 to over 59 months. Eight patients had extensive metastases at the beginning of treatment: they at first received only chemotherapy, followed by radiotherapy or operation, as indicated. Full clinical remission was achieved in five of them: in three this remission has now lasted for more than 18, 40 and 44 months, respectively. These results indicate that (1) additional chemotherapy improves the prognosis of localized Ewing's sarcoma, and (2) even in far-progressed cases the combination of chemotherapy and radiotherapy can achieve lasting remission, which may in fact be a true cure.

Adolescent↗
PubMed1979

The rate of sister chromatid exchange in normal human bone marrow cells.

Sister chromatid exchange (SCE) was studied in bone marrow cells of six healthy individuals. Compared with peripheral blood lymphocytes, a remarkably low and constant rate of SCEs was observed, ranging from 3.64 to 4.65 per metaphase. The lower incidence of SCE can be related only partly to the higher contraction of bone marrow cells and the shorter exposure time to BUdR. Rather, a cell-specific phenomenon is suggested.

Adult↗
PubMed1979

Malignant granular cell tumor.

The malignant granular cell tumor ist a rare soft tissue neoplasia which is chiefly localized in the sceletal muscles. The uncertain histogenesis gave rise to different terms. The clinical course is often protracted but fatal. Diagnosis, differential diagnosis, and treatment are discussed in the light of a case report concerning a malignant granular cell tumor in a 28-year-old man.

Adenocarcinoma↗
PubMed1979

Quantitation of immune complexes by nephelometry.

Laser nephelometry was used to quantitate immune complexes and IgG aggregates in native sera. Sensitivity limits and calibration curves were in good agreement with the C1q binding assay frequently used for measuring immune complexes. Distinction between sera containing lipids or immune complexes was achieved by polyethylene glycol precipitation. Although not superior to other methods for quantitating immune complexes, the nephelometric assay may prove useful as a screening test and has the potential of an antigen-specific immune complex assay.

Animals↗
PubMed1979

[Results of emission computerised axial tomography of the liver in 113 patients (author's transl)].

Transversal emission computerised axial tomography (ECAT) was performed in addition to bioptic examination in 113 patients with solid tumours and lyphomas. In 69/113 (61%) patients the results of conventional scintigraphy and ECAT were in agreement. In 44/113 (39%) patients additional information was obtained. Correct positive and correct negative results were found in 86.3% (63.6% and 22.7%, respectively), while in 13.6% the results were false positive or false negative (6.8% both).

Adult↗
PubMed1978

[Idiopathic thrombocytopenic purpura in Hodgkin's disease--an early sign of a recurrence (author's transl)].

Idiopathic thrombocytopenic purpura (ITP) in the course of Hodgkin's disease is generally judged to be a paraneoplastic immune phenomenon. This concept finds support in the observation of a patient who developed simultaneously a recurrence of ITP and a protein anomaly in the form of an alpha-chain protein. Combined chemotherapy brought about remission of the Hodgkin's disease at the same time as normalisation of the platelet values and disappearance of the alpha-chain protein. There is no necessary correlation between tumour activity and ITP. But if ITP is observed, the most effective means would seem to be rigorous treatment of the Hodgkin's disease.

Adult↗